##  [Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients](/us-en/news/media-releases/novartis-announces-fda-filing-acceptance-siponimod-baf312-first-and-only-oral-drug-shown-delay-disability-progression-typical-spms-patients-0 "Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients") 

  Oct 08, 2018